• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Global Hormone Replacement Therapy Market 2014-2018 - Product Image

Global Hormone Replacement Therapy Market 2014-2018

  • ID: 2889852
  • July 2014
  • Region: Global
  • 87 pages
  • TechNavio

FEATURED COMPANIES

  • Abbott Laboratories Ltd.
  • Actavis plc
  • Amgen Inc.
  • ANI Pharmaceuticals Inc.
  • Bayer AG
  • Merck & Co. Inc.
  • MORE

About Hormone Replacement Therapy

Hormone replacement therapy, also known as hormone therapy, is a means of replacing hormones that are no longer being produced by the body. This type of therapy is usually initiated at menopause or may be started while a woman is in the perimenopausal phase, nearing menopause. Hormone replacement therapy replenishes the hormones required by the human body to function by using bio-identical hormones. The therapy contains estrogen and progesterone, and in some cases testosterone, to reduce symptoms of menopause. This replacement therapy may also protect against osteoporosis, reduce the risk of coronary heart disease, and may prevent or delay the onset of Alzheimer's disease. Replacement therapy can also increase the chance of developing more serious health complications such as blood clots, breast cancer, uterine cancer, and bowel cancer.

The analysts forecast the Global Hormone Replacement Therapy market will grow at a CAGR of 2.51 percent over the period 2013-2018.

Covered in this Report
The Global Hormone Replacement Therapy market can be divided into three segments: Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories Ltd.
  • Actavis plc
  • Amgen Inc.
  • ANI Pharmaceuticals Inc.
  • Bayer AG
  • Merck & Co. Inc.
  • MORE

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Type of Therapy
08. Geographical Segmentation
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Key News
16.1.2 Mergers and Acquisitions
16.2 Market Share Analysis 2013
16.3 Other Prominent Vendors
17. Key Vendor Analysis
17.1 Actavis plc
17.1.1 Key Facts
17.1.2 Business Description
17.1.3 Business Segmentation
17.1.4 Business Segmentation by Revenue 2012 and 2013
17.1.5 Sales by Geography
17.1.6 Business Strategy
17.1.7 Key Information
17.1.8 SWOT Analysis
17.1.9 Strengths
17.1.10 Weaknesses
17.1.11 Opportunities
17.1.12 Threats
17.2 Bayer AG
17.2.1 Key Facts
17.2.2 Business Overview
17.2.3 Business Segmentation
17.2.4 Business Strategy
17.2.5 Sales Segmentation by Business
17.2.6 Sales by Geographical Segmentation
17.2.7 Key Information
17.2.8 SWOT Analysis
17.2.9 Strengths
17.2.10 Weaknesses
17.2.11 Opportunities
17.2.12 Threats
17.3 Merck & Co. Inc.
17.3.1 Key Facts
17.3.2 Business Overview
17.3.3 Business Segmentation by Revenue 2013
17.3.4 Business Segmentation by Revenue 2012 and 2013
17.3.5 Sales by Geography
17.3.6 Business Strategy
17.3.7 Key Developments
17.3.8 SWOT Analysis
17.3.9 Strengths
17.3.10 Weaknesses
17.3.11 Opportunities
17.3.12 Threats
17.4 Novartis AG
17.4.1 Key Facts
17.4.2 Business Overview
17.4.3 Business Segmentation by Revenue 2013
17.4.4 Business Segmentation by Revenue 2012 and 2013
17.4.5 Sales by Geography
17.4.6 Business Strategy
17.4.7 Key Developments
17.4.8 SWOT Analysis
17.4.9 Strengths
17.4.10 Weaknesses
17.4.11 Opportunities
17.4.12 Threats
17.5 Novo Nordisk A/S
17.5.1 Key Facts
17.5.2 Business Overview
17.5.3 Business Segmentation by Revenue 2013
17.5.4 Business Segmentation by Revenue 2012 and 2013
17.5.5 Sales by Geography
17.5.6 Business Strategy
17.5.7 Key Information
17.5.8 SWOT Analysis
17.5.9 Strengths
17.5.10 Weakness
17.5.11 Opportunities
17.5.12 Threats
17.6 Pfizer Inc.
17.6.1 Key Facts
17.6.2 Business Overview
17.6.3 Business Segmentation by Revenue 2013
17.6.4 Business Segmentation by Revenue 2012 and 2013
17.6.5 Sales by Geography
17.6.6 Business Strategy
17.6.7 Key Developments
17.6.8 SWOT Analysis
17.6.9 Strengths
17.6.10 Weaknesses
17.6.11 Opportunities
17.6.12 Threats
18. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Hormone Replacement Therapy Market 2013-2018 (US$ billion)
Exhibit 3: Global Hormone Replacement Therapy Market by Type of Therapy
Exhibit 5: Global Hormone Replacement Therapy Market by Geographical Segmentation 2013
Exhibit 6: Global Hormone Replacement Therapy marketBusiness Segmentation 2013
Exhibit 7: Global Hormone Replacement Therapy market Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 8: Actavis Plc: Sales by Geography (in US$ million)
Exhibit 9: Business Segmentation of Bayer AG 2013
Exhibit 10: Sales Comparison of Bayer AG by Business Segment 2012 and 2013 (US$ million)
Exhibit 11: Sales Segmentation of Bayer AG by Geography 2013
Exhibit 12: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 13: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 14: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 15: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 16: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 17: Novartis AG: Sales by Geography 2013
Exhibit 18: Novo Nordisk A/S: Business Segmentation by Revenue 2013
Exhibit 19: Novo Nordisk A/S: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 20: Novo Nordisk A/S: Sales by Geography 2013
Exhibit 21: Pfizer Inc.: Business Segmentation by Revenue 2013
Exhibit 22: Pfizer Inc.: Business Segmentation by Revenue 2012 and 2013
Exhibit 23: Pfizer Inc.: Sales by Geography 2013

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories Ltd.
  • Actavis plc
  • Amgen Inc.
  • ANI Pharmaceuticals Inc.
  • Bayer AG
  • Merck & Co. Inc.
  • MORE

Commenting on the report, an analyst from the team said: “The Global Hormone Replacement Therapy market is experiencing increased interest in non-hormonal therapies. This trend shift toward non-hormonal therapies for menopausal symptoms and osteoporosis has been apparent since the Women’s Health Initiative Study in 2002. In 2013, the US FDA approved the first non-hormonal treatment, Brisdelle (paroxetine), to treat vasomotor symptoms associated with menopause”.

According to the report, one of the main drivers in this market is the significant unmet need for HRT. The current treatment options are incapable of meeting the market requirements because of their lower safety profiles, leaving a large amount of unmet need in this market. The need for new treatment options with better safety results to address the current unmet need is huge.

Further, the report states that the Global HRT market faces some serious challenges. One of the main challenges is the high cost of HRT, which hinders its acceptance by patients. Many patients do not have the required budget to invest in high-cost treatment options. Adverse side effects of HRT are another major factor hampering the growth of the Global HRT market.

The report also includes a discussion of the other vendors operating in this market. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Note: Product cover images may vary from those shown

- Actavis plc
- Bayer AG
- Merck & Co. Inc.
- Novartis AG
- Novo Nordisk A/S
- Abbott Laboratories Ltd.
- Amgen Inc.
- ANI Pharmaceuticals Inc.
- Hisamitsu Pharmaceutical Co. Inc.
- MylanLaboratories Inc.
- Orion Corp.
- QuatRx Pharmaceuticals Co.
- Teva Pharmaceutical Industries Ltd.
- TherapeuticsMD Inc.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos